Shots:
- IRLAB to receive ~$363M, including $28M as up front and ~$335M as development, regulatory and commercial milestones along with royalties on WW net sales of mesdopetam
- Ipsen get the exclusive WW rights to develop and commercialize mesdopetam (novel dopamine D3-receptor antagonist) which is currently being evaluated in P- IIb clinical trials for patients with PD experiencing LID
- IRLAB will be responsible for the ongoing P-IIb trial while Ipsen will initiate P- III preparatory activities, and is responsible for all remaining clinical development and commercialization globally
Click here to read full press release/ article | Ref: Ipsen | Image: Genetic Engineering and Biotechnology News
The post Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease first appeared on PharmaShots.
